UnitedHealthcare weight-loss drug coverage rules take effect with BMI 30 threshold
The updated rules set how the insurer reviews weight-loss prescriptions, including a 5 percent weight-loss requirement at renewal for most of the listed drugs.
UnitedHealthcare's updated prior authorization program for weight-loss and appetite-suppression medications took effect Sept. 1, 2026, setting the clinical criteria the company uses to review coverage requests for drugs including Wegovy, Zepbound and Foundayo [1]. The program is numbered 2026 P 1114-22 [1].
The program is optional. It applies to clients and businesses that have elected to cover weight-loss products with prior authorization, and UnitedHealthcare says it is also designed to meet regulatory requirements for weight-loss medication coverage in California, New Mexico, North Dakota Essential Health Benefits plans and New York [1]. The medication list includes phentermine (all brands, including Adipex-P and Lomaira), benzphetamine, Contrave, diethylpropion, Foundayo (orforglipron), phendimetrazine, Xenical, Qsymia, Saxenda (liraglutide), Wegovy (semaglutide) injection, Wegovy tablet, Wegovy HD and Zepbound (tirzepatide) [1].
For initial approval, members generally must have a body mass index of 30 or higher, or 27 or higher along with a weight-related condition such as dyslipidemia, hypertension, type 2 diabetes or sleep apnea [1]. Pediatric patients can qualify with a BMI at or above the 95th percentile [1]. The BMI rules list one exception: Wegovy injection requested to treat metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis, stage F2 or F3 [1]. Zepbound for moderate to severe obstructive sleep apnea is listed as a qualifying reason for treatment, but the BMI section lists no matching exception for that use [1].
Treatment also must be used alongside lifestyle modification, such as dietary changes, exercise, behavioral support or a community-based program [1]. Age minimums are 12 and older for Qsymia, Saxenda, Wegovy injection and Xenical, and older than 16 for the other medications [1].
Approval periods differ by drug. Sympathomimetics — benzphetamine, diethylpropion, phendimetrazine and phentermine — get 3 months; Contrave, Qsymia and Saxenda get 4 months; Wegovy injection, Wegovy tablet and Wegovy HD get 5 months; and Foundayo, Xenical and Zepbound get 6 months [1].
To renew, patients must show weight loss from their starting weight: at least 5 percent for Wegovy injection, Wegovy tablet and Wegovy HD, and at least 5 percent for “all other appetite suppressants,” a group that includes Zepbound, Foundayo, Contrave and Xenical [1]. Saxenda renewals require at least 4 percent weight loss, and Qsymia renewals require at least 3 percent [1]. Renewals for Contrave, Foundayo, Qsymia, Saxenda, Wegovy and Zepbound are issued for 12 months; phentermine and the other stimulant-type drugs are renewed for 6 months [1]. For Wegovy prescribed for MASH, renewal requires a documented positive clinical response, such as improvement in or stabilization of fibrosis, and that the patient has not progressed to cirrhosis [1].
A separate section covers North Dakota fully insured Essential Health Benefits plans for small groups and individuals. There, the BMI threshold is 40 or higher, or 120 percent of the 95th percentile for pediatric patients, and a MASH diagnosis removes the BMI requirement for Wegovy injection [1]. Reauthorization in that section requires at least 5 percent weight loss for Zepbound [1].
UnitedHealthcare notes that state mandates, federal requirements and a member's specific benefit plan can affect coverage, that supply limits may be in place, and that Foundayo and Wegovy tablet “may be in Exclude at Launch” [1].
Why it matters for patients
The program only applies to plans whose sponsors chose to offer weight-loss coverage with prior authorization, and it does not say which clients have adopted it or how many members it affects [1].
The approval windows mean re-review dates vary by product. A patient on Wegovy injection faces an earlier coverage check than a patient on Zepbound or Foundayo, because initial approvals run 5 months for Wegovy and 6 months for the other two [1].
Renewal is tied to results. For most of the listed drugs, continued coverage depends on documented weight loss of at least 5 percent and on continued lifestyle modification, so records of weight and follow-up care are part of the paperwork [1]. For Wegovy used for MASH, the measure is liver response rather than weight, and progression to cirrhosis is listed as a reason renewal would not meet the criteria [1].
What happens to a patient who does not meet a renewal threshold is not described in the program document [1].
What happens next
The listed effective date is Sept. 1, 2026 [1]. The document shows a pattern of annual updates, with earlier revisions dated 2024 and 2025, but it lists no future effective dates or review schedule beyond this one [1]. Renewal decisions will fall at the end of each member's authorization period, which depends on when treatment started [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.